Chief Executive Officer

Andy Kidd, M.D., joins Tentarix Biotherapeutics as Chief Executive Officer. He was previously President and CEO of Aptinyx Inc., a CNS-focused biotechnology company, where he played a leading role in taking the company public and advancing several programs into clinical development. Previously, he held a series of senior leadership positions at Baxter International, in both general management and corporate development.  He began his career in the healthcare practice of The Boston Consulting Group, based in London and Chicago. He holds an M.D. from the University of Oxford, a B.A. in medical sciences from the University of Cambridge and is a Chartered Financial Analyst.